Payment overview · 2025
General Payments
$372.08
20 reported records · 13 companies
Healthcare provider profile · identity verified
Thomas L Colvin, MD
Allopathic & Osteopathic Physicians|Family Medicine · WINNSBORO, LA · NPI 1982670733
Verified facts
What the public records show
CMS Open Payments records show Thomas L Colvin, MD received $372.08 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 549 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69.59 | 18.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.05 | 17.5% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.72 | 9.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.76 | 9.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.24 | 8.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.16 | 5.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.98 | 4.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.97 | 4.8% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $16.85 | 4.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.27 | 4.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.01 | 4.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.91 | 4.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.57 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $372.08 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $65.05 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $54.93 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $36.72 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.76 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 549 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 175 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
115 | 34 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
135 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
115 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
175 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 25 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
175 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
549 | 68 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 867 | 167 |
| Levothyroxine Sodium | Levothyroxine Sodium | 672 | 130 |
| Furosemide | Furosemide | 644 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 584 | 126 |
| Eliquis | Apixaban | 549 | 68 |
| Potassium Chloride | Potassium Chloride | 549 | 111 |
| Losartan Potassium | Losartan Potassium | 523 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 480 | 85 |
| Trazodone Hcl | Trazodone Hcl | 464 | 88 |
| Gabapentin | Gabapentin | 462 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 435 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 432 | 77 |
| Omeprazole | Omeprazole | 418 | 107 |
| Lisinopril | Lisinopril | 403 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 395 | 82 |
| Montelukast Sodium | Montelukast Sodium | 390 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 325 | 75 |
| Metformin Hcl | Metformin Hcl | 314 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 301 | 88 |
| Nifedipine Er | Nifedipine | 293 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 286 | 60 |
| Donepezil Hcl | Donepezil Hcl | 285 | 50 |
| Famotidine | Famotidine | 285 | 42 |
| Memantine Hcl | Memantine Hcl | 284 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 272 | 68 |
| Glimepiride | Glimepiride | 254 | 65 |
| Quetiapine Fumarate | Quetiapine Fumarate | 238 | 49 |
| Sertraline Hcl | Sertraline Hcl | 218 | 37 |
| Mirtazapine | Mirtazapine | 215 | 25 |
| Allopurinol | Allopurinol | 208 | 38 |
| Carvedilol | Carvedilol | 205 | 45 |
| Celecoxib | Celecoxib | 199 | 68 |
| Pioglitazone Hcl | Pioglitazone Hcl | 190 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 181 | 52 |
| Ezetimibe | Ezetimibe | 177 | 57 |
| Rexulti | Brexpiprazole | 175 | 14 |
| Entresto | Sacubitril/Valsartan | 163 | 19 |
| Buspirone Hcl | Buspirone Hcl | 160 | 38 |
| Simvastatin | Simvastatin | 153 | 26 |
| Risperidone | Risperidone | 145 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 28 |
| Levetiracetam | Levetiracetam | 138 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 30 |
| Mounjaro | Tirzepatide | 135 | 29 |
| Rivastigmine | Rivastigmine Tartrate | 131 | 15 |
| Clonidine Hcl | Clonidine Hcl | 128 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 126 | 28 |
| Spironolactone | Spironolactone | 117 | 19 |
| Linzess | Linaclotide | 115 | 34 |
| Trulicity | Dulaglutide | 115 | 16 |
| Bumetanide | Bumetanide | 114 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 43 |
| Pregabalin | Pregabalin | 111 | 32 |
| Meloxicam | Meloxicam | 110 | 36 |
| Jardiance | Empagliflozin | 107 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 101 | 22 |
| Fluconazole | Fluconazole | 101 | 66 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 100 | 14 |
| Myrbetriq | Mirabegron | 96 | 14 |
| Ozempic | Semaglutide | 95 | 25 |
| Baclofen | Baclofen | 92 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 35 |
| Ceftriaxone | Ceftriaxone Sodium | 88 | 53 |
| Amiodarone Hcl | Amiodarone Hcl | 85 | 17 |
| Azithromycin | Azithromycin | 85 | 69 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 28 |
| Divalproex Sodium | Divalproex Sodium | 82 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 25 |
| Tramadol Hcl | Tramadol Hcl | 79 | 23 |
| Colestipol Hcl | Colestipol Hcl | 76 | 21 |
| Farxiga | Dapagliflozin Propanediol | 76 | 13 |
| Januvia | Sitagliptin Phosphate | 74 | suppressed |
| Finasteride | Finasteride | 72 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 70 | 18 |
| Sucralfate | Sucralfate | 66 | 17 |
| Olanzapine | Olanzapine | 65 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 24 |
| Warfarin Sodium | Warfarin Sodium | 63 | suppressed |
| Metolazone | Metolazone | 62 | 27 |
| Atenolol | Atenolol | 61 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | 17 |
| Doxepin Hcl | Doxepin Hcl | 60 | 15 |
| Prednisone | Prednisone | 60 | 28 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 42 |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 56 | 16 |
| Ondansetron Odt | Ondansetron | 55 | 41 |
| Oxcarbazepine | Oxcarbazepine | 55 | suppressed |
| Tradjenta | Linagliptin | 55 | suppressed |
| Alprazolam | Alprazolam | 54 | 19 |
| Meclizine Hcl | Meclizine Hcl | 54 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 13 |
| Rivastigmine | Rivastigmine | 53 | 11 |
| Digoxin | Digoxin | 52 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 51 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 33 |
| Ibuprofen | Ibuprofen | 50 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Amantadine | Amantadine Hcl | 48 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 47 | suppressed |
| Invokana | Canagliflozin | 47 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 47 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 16 |
| Bupropion Xl | Bupropion Hcl | 46 | suppressed |
| Novolog Flexpen | Insulin Aspart | 46 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Naproxen | Naproxen | 44 | suppressed |
| Estradiol | Estradiol | 43 | 13 |
| Nystatin | Nystatin | 42 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Clonidine | Clonidine | 40 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 40 | suppressed |
| Mupirocin | Mupirocin | 39 | 18 |
| Pentoxifylline | Pentoxifylline | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Metronidazole | Metronidazole | 38 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 35 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | 11 |
| Colchicine | Colchicine | 35 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 18 |
| Lorazepam | Lorazepam | 32 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 25 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | 15 |
| Promethazine Hcl | Promethazine Hcl | 31 | 12 |
| Lactulose | Lactulose | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 18 |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 24 |
| Cephalexin | Cephalexin | 28 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 20 |
| Divalproex Sodium Er | Divalproex Sodium | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Minoxidil | Minoxidil | 28 | suppressed |
| Propylthiouracil | Propylthiouracil | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 23 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Nexletol | Bempedoic Acid | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 22 | 14 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 11 |
| Theophylline Er | Theophylline Anhydrous | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 16 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 19 | 14 |
| Valsartan | Valsartan | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Edarbi | Azilsartan Medoxomil | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | 15 |
| Torsemide | Torsemide | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Toprol Xl | Metoprolol Succinate | 13 | suppressed |
| Acetazolamide Er | Acetazolamide | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $372.08 · 20 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Cologuard Collection Kit, ELIQUIS, JARDIANCE, KEVEYIS, Kerendia, MOUNJARO, NURTEC ODT, Omnipod, Ozempic, Qelbree, REXULTI, Rybelsus, VRAYLAR, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error